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Improved Metered Dose Inhaler Technique
When a Coordination Cap Is Used
Wahida Azouz, MSc,1 Jessica Campbell, MPharm,1 John Stephenson, PhD,2
Dinesh Saralaya, MD, FRCP,3 and Henry Chrystyn, PhD1
Abstract
Background: Patients often experience problems using metered dose inhalers (MDIs), particularly poor coor-
dination between inhalation start and dose actuation (TsIn: time difference between the start of an inhalation and
the actuation of a dose), and fast peak inspiratory flow (PIF). We investigated if a coordination cap (CAP), with
instruction to prolong inhalation, solved these problems.
Methods: Inhalation profiles [PIF, TsIn, inhalation volume (Vi), inhalation time (Ti)] of patients with stable
asthma prescribed an MDI were measured using their real-life technique (MDI). Inhalation profiles were then
measured with the cap fitted (MDI +CAP). These patients were then instructed to inhale through the MDI +CAP
for 5 sec, and inhalation profiles measured (MDI +CAP +TRAIN). TsIn was only measured for the MDI.
Results: Resistances of MDI and MDI +CAP were 0.0135 and 0.0243 (cm H2O)
½/(L/min), respectively. Seventy-
one patients were evaluated, with mean [standard deviation (SD)] forced expiratory volume over 1 sec %
predicted normal of 78.3% (21.0). Following MDI, MDI +CAP, and MDI +CAP +TRAIN: mean (SD) PIF was
155.6 (61.5), 112.3 (48.4), and 73.8 (34.9) L/min, respectively ( p < 0.001); mean (SD) Ti was 1.60 (0.60), 1.92 (0.80),
and 2.99 (1.03) sec, respectively ( p < 0.001); and Vi was similar between stages. Twelve patients used a slow flow
with the MDI alone, but only two of these patients demonstrated good coordination. With the cap in place
(which ensures good coordination), the number of patients using a slow flow increased to 25 for MDI +CAP and
to 50 following MDI +CAP +TRAIN.
Conclusions: The cap with its effect of increasing resistance to airflow combined with the instruction to prolong
inhalation time significantly decreased the inhalation flow.
Key words: asthma, inhalation flow, device, I-Breathe
Introduction
The metered dose inhaler (MDI) has been the mostwidely used inhaler over the past 40 years, and the
problems patients experience with correct inhaler technique
are the same today as they were when the MDI was first
introduced.(1–6) Although large volume spacers and an open-
mouth technique have been used to help with coordination,
these problems still exist.(1) It has been shown that poor MDI
technique is related to poor asthma control(7,8) and hospitali-
zation.(2) The recommended inhalation procedure for an MDI
involves several steps (Table 1),(9) and of these, good coordi-
nation and a slow inhalation flow maintained for as long as
possible are particularly important for achieving good asthma
control.(7) Lung deposition is reduced when there is poor co-
ordination between the actuation of the dose and the start of
inhalation(10) and when a fast inhalation flow is used.(11,12) A
breath hold at the end of the inhalation(11,12) and increased
inhalation volume(12,13) both improve lung deposition.
Most studies assessing MDI technique use subjective
methods,(1–3) but some have used more objective, electronic
methods.(14–16) Only 8% of patients use a good inhaler
technique with their MDI,(7) and although inhalation tech-
nique training can be useful,(7) in some cases it may have
little effect,(14) or improvements are temporary.(17) Breath-
actuated inhalers solve the problem of poor coordination,(10)
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but are currently only available for the delivery of salbuta-
mol and beclomethasone.
A flexible coordination cap, the I-Breathe (patent no. PCT/
EP2011/006000), shown in Figure 1, has been designed to fit
onto an MDI with an airtight seal, such that an inhalation
cannot start until the canister is pressed. Pressing the canister
causes slits in the coordination cap to open (as it becomes
compressed), thereby allowing airflow. This coordination cap
therefore converts the MDI into an inhalation co-ordinating
device, by preventing inhalation prior to actuation. The
coordination cap has been designed for use with existing
familiar inhalers. In this prospective, investigational study, we
have measured the inhalation parameters of asthma patients
using an MDI to identify if these parameters change when the
coordination cap is fitted. We have extended this to determine
if a short training session to increase the patients’ inhalation
times in addition to the coordination cap helps to decrease
their inhalation flow.
Materials and Methods
Patient demographics and baseline characteristics
Ethical committee approvalwas received from the Yorkshire
and Humber Research Ethics Committee–Bradford (reference
09/H1302/64) and from the University of Huddersfield
(SASEC/10/01). The study was conducted in accordance with
theDeclaration ofHelsinki and the International Conference on
Harmonization Guidelines for Good Clinical Practice.(18) Eli-
gible patients had stable asthma, were 18–45 years old, and
were prescribed an MDI. Those with an acute exacerbation, an
infection, or viral illness in the preceding 4 weeks were ex-
cluded. All patients provided written, informed consent prior
to participation. Patients’ demographic data and medication
usage were recorded. Their spirometry was measured using a
ONE FLOW spirometer (Clement Clarke International Ltd.,
Harlow, UK), and they each completed the Asthma Control
Questionnaire (ACQ).(19,20)
Table 1. Instructions for Ideal Inhaler Technique with an MDI
Step Instruction
1 Shake 4 or 5 times if suspension formulation.
2 Take the cap off the mouthpiece.
3 Prime the inhaler (refer to the PIL for specific instructions).
4 Exhale slowly, as far as comfortable (to empty the lungs).
5 Hold the inhaler in an upright position.
6 Immediately place the inhaler in the mouth between the teeth and on top of the tongue.
7 Ensure that the lips have formed a good seal with the mouthpiece.
8 Start to inhale slowly, through the mouth, and at the same time press the canister to actuate a dose.
9 Maintain a slow and deep inhalation, through the mouth, until the lungs are full of air. This should take an
adult 4–5 sec.
10 At the end of the inhalation, take the inhaler out of the mouth and close the lips.
11 Continue to hold the breath for as long as possible, or up to 10 sec before breathing out.
12 Now breathe normally.
13 If another dose is required, repeat steps 4–12.
PIL, patient information leaflet.(9)
FIG. 1. The I-Breathe coordination
cap. (A) The assembled MDI with
coordination cap fitted, ready to use.
(B–D) Components of the MDI plus
coordination cap. pMDI, pressurized
metered dose inhaler.
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Study design and inhalation parameters
An empty MDI was adapted to enable a patient’s inhala-
tion profile to be recorded. Figure 2 describes a typical in-
halation flow profile when using an MDI. The inhalation
flow increases rapidly and then plateaus before falling away
at the end of the inhalation. This profile shows when the
point of actuation occurs after the start of inhalation. The
empty MDI was encased onto the air inlet of a pneumo-
tachograph (Cardinal Health GmbH). Flow and time mea-
surements during an inhalation were downloaded in a
Microsoft Excel spreadsheet to compute the inhalation pro-
file. Figure 2 highlights how each profile was used to de-
termine the study primary outcome, peak inspiratory flow
(PIF; liters per minute), and the secondary outcomes, inha-
lation volume (Vi; liters) and inhalation time (Ti; seconds). A
ratio of Vi/forced vital capacity (FVC) was calculated to
indicate the depth of inhalation. The time between the start
of an inhalation and pressing the canister was defined as
TsIn (seconds). The inhalation time starts at the beginning of
an inhalation. Figure 2 shows actuation that occurs after the
start of an inhalation, and so TsIn is positive. If actuation
occurred at the start of an inhalation, then this would be
represented on Figure 2 as a TsIn of zero, and thus the line
indicating actuation would be shown at the start of the in-
halation flow. If actuation occurred before the start of an
inhalation, then this line would be shown before the start of
inhalation and TsIn would be negative.
Slow inhalation flow was defined as PIF of < 90L/
min(11,14,21) and good coordination as TsIn of 0–0.2 sec.(14,21)
A deep inhalation was defined as a Vi/FVC ratio of > 0.6.(15)
All procedures were carried out during a single visit. Each
patient performed the following inhalation procedures, and
their inhalation profiles were measured:
 MDI alone: patients inhaled through an empty MDI
using their normal day-to-day technique.
 MDI +CAP: patients inhaled through the empty MDI
fitted with the coordination cap, using their normal day-
to-day technique. They were informed that the coordi-
nation cap would not allow inhalation until it was de-
pressed. Also, if they started an inhalation before
actuating the canister, they would notice a vacuum that
would be released when they depressed the canister. In
addition, if the patient released the canister before the
end of their inhalation, the slits in the cap would close
and block any further inhalation through the MDI. If
this did occur, the patient was instructed to keep the
canister depressed until the end of their inhalation. This
instruction was only given once to the patient.
 MDI +CAP +TRAIN: each patient was then trained to
increase the length of their inhalation to 5 sec. This was
done by the trainer demonstrating a slow inhalation
while they counted to 5 and then practiced once by the
patient. Patients then used the MDI fitted with the co-
ordination cap after this training.
Each inhalation was performed twice, and the flow pro-
file with the slower PIF was chosen for data analysis. TsIn
could not be measured for MDI +CAP or MDI +CAP +
TRAIN. The reason for this is because the mechanism used
to measure TsIn allows a small airflow, and so would not be
airtight against the MDI if the cap was in place. Such air
leakage would negate the airtight seal between the MDI and
the cap in the measurement system. This was therefore
disconnected.
Patient satisfaction
Following the inhalations, a 5-point Likert scale was used
to obtain patient satisfaction about using an MDI with the
coordination cap. Patients were also asked if they perceived
any advantages or disadvantages when using the coordina-
tion cap with their MDI.
Resistance of devices
The resistance of the MDI with and without the coordi-
nation cap was determined by measuring the pressure
change corresponding to flows of 10–100 L/min as described
by Clark and Hollingworth.(22)
Statistical analysis
A series of repeated measures analyses of covariance
(ANCOVA) models was derived to assess the effect of the
procedures MDI +CAP and MDI +CAP +TRAIN on the use
of an MDI, with respect to the primary outcome measure of
PIF and the secondary outcome measures of Vi and Ti,
controlling for all measured factors and covariates [age,
gender, FVC, and peak expiratory flow rate (PEFR)]. Forced
expiratory volume over 1 sec (FEV1) was excluded because it
showed extreme colinearity with FVC, and hence in a re-
gression model could lead to model instability and, in ad-
dition, its association was not as strong as FVC. All
covariates were centered to avoid altering the main effect of
the condition in any cases where covariate variability was
large compared with condition variability. An additional
series of controlled ANCOVA models was derived using the
outcome measure Vi standardized by FVC. In these models,
FVC was not included as a covariate.
An uncontrolled multivariate general linear model (GLM)
was also performed on baseline data (MDI alone), consid-
ering the relationship between the single predictor FVC and
a linear combination of the three outcome measures, with
follow-up univariate models derived as appropriate.
Results
The measured resistance for the empty MDI without the
coordination cap was 0.0135 (cm H2O)
½/(L/min) and 0.0243
FIG. 2. An inhalation profile using an MDI measured by
the inhalation profile recorder.
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(cm H2O)
½/(L/min) for the MDI with the coordination cap
while the canister was depressed.
Seventy-one patients were recruited, and all completed the
study inhalation maneuvers; their baseline characteristics
and spirometry measurements are listed in Table 2. The
mean [standard deviation (SD)] ACQ score was 1.32 (0.71)
with 16 patients scoring < 0.75, 30 patients scoring 0.75–1.5,
and 25 patients scoring > 1.5.
There was no statistical difference between the inhalation
profiles for the slow and fast PIF recorded for each patient.
Table 3 summarizes patients’ inhalation parameters for the
slow PIF inhalation profile recorded. For individual param-
eters, statistical analysis revealed pairwise differences cor-
rected for multiple comparisons ( p< 0.001) between
inhalation procedures for PIF and Ti, but not for Vi, shown in
Figure 3. Table 4 shows the number of patients performing a
slow ( < 90 L/min), fast (90–200 L/min), and very fast
( > 200 L/min) inhalation flow. Table 5 shows the number of
patients who achieved a deep inhalation for each procedure,
as determined by their Vi/FVC ratio.
With the MDI alone, TsIn values ranged from - 2.40 sec
(actuation before inhalation) to 1.71 sec (actuation after the
start of the inhalation). Ten (14.1%) patients had a negative
TsIn (TsIn - 0.04 to - 2.40 sec), indicating early actuation,
and 25 (35.2%) patients had a late actuation (TsIn 0.24 to
1.71 sec), whereas 36 (50.7%) used the MDI with good coor-
dination. Of these 36 patients, only two had PIF of < 90 L/
min; therefore, 2/71 (2.8%) demonstrated good inhalation
technique with the MDI alone.
Patients were asked on a scale of 1 to 5 how satisfied they
would be to use the coordination cap with their MDI in daily
life (1=unsatisfied, 5 = very satisfied). Seven patients gave a
score of 3, 21 patients gave a score of 4, and 43 were very
satisfied (score of 5).
The first time the MDI was fitted with the coordination
cap, 17 patients had to be instructed to keep the canister
depressed throughout the duration of their inhalation. The
inhalation procedure was repeated, and these patients did
not repeat the error for all the remaining inhalations.
An uncontrolled GLM assessing the effect of FVC on the
MDI outcome measures indicated a significant association
between FVC and the outcome measures assessed jointly
(L = 0.651; F(3,67) = 12.0; p < 0.001). Subsequent follow-up
univariate GLMs identified significant associations between
FVC and PIF (F(1,69) = 8.09; p= 0.006) and between FVC and
Vi (F(1,69)= 36.3; p= 0.001). The association between FVC and
Ti was not statistically significant (r= 0.214; p = 0.073). The
correlations between PIF and FVC, and between Vi and FVC,
are shown in Figure 4.
Discussion
Overall, for the MDI alone, 50.7% of the patients achieved
good coordination and 70.4% had a Vi/FVC ratio of > 0.6,
indicating a full inhalation, but only 16.9% inhaled slowly
through the MDI. The proportion of patients with poor co-
ordination was consistent with previous reports that used
subjective methods,(1–3,7,24) whereas the proportion of those
with good coordination and slow flow is similar to that re-
ported in a study involving 432 asthmatics.(6) The results
confirm previous studies showing that too rapid inhalation is
the most common mistake made by patients.(7,24) Most pa-
tients had stable mild–moderate asthma (mean FEV1 %
predicted value of 78%), and only 16 had good self-reported
asthma control (ACQ < 0.75). With the cap fitted to the MDI
and inclusion of a simple verbal instruction, where the pa-
tient is asked to increase inhalation duration to 5 sec, most
patients could achieve a sufficiently slow inhalation flow
with good coordination. As asthma control and hospitaliza-
tion are related to inhaler technique,(1,7,8) use of the coordi-
nation cap and the instruction to extend inhalation to 5 sec
could therefore improve technique and ultimately asthma
control. These improvements could thus contribute to the
challenge by the Global Initiative for Asthma to reduce
hospitalizations by 50% over a 5-year period.(25)
We chose 0–0.2 sec for TsIn to represent good coordination,
which is in line with that previously reported.(14) This is con-
solidated by the study reported by Farr et al.(21) In this study,
medium early actuation provided greater lung deposition
versus slow/early or fast/late actuation. Medium early was
defined as actuation at 90L/min when 300mL had been in-
haled, which corresponds to a time of 0.2 sec. Furthermore, as
empty MDI canisters were used, any inhalation problems due
to the ‘‘cold Freon effect’’ did not occur.(6)
The slower inhalation flow achieved with the coordination
cap fitted compared with the MDI alone was due to the in-
creased airflow resistance caused by the cap, and resulted in
the slightly longer inhalation time. This suggests that new
Table 2. Mean (SD) Patient Demographics
and Baseline Characteristics
Characteristic N = 71
Males, n 19
Age, years 32.0 (13.5)
Weight, kg 74.4 (12.8)
Height, cm 167.5 (9.7)
PEFR
Actual, L/min 355.5 (108.1)
% predicted(23) 74.8 (23.3)
FVC
Actual, L 3.46 (1.04)
% predicted(23) 82.4 (22.0)
FEV1
Actual, L 2.81 (0.85)
% predicted(23) 78.3 (21.0)
PEFR, peak expiratory flow rate.
Table 3. Mean (SD) Inhalation Parameters
for Patients Using an MDI with or without
the Coordination Cap










155.6 (61.5) 112.3 (48.4) 73.8 (34.9) < 0.001
Vi, L 2.33 (0.84) 2.26 (0.86) 2.30 (0.79) 0.651
Ti, sec 1.60 (0.60) 1.92 (0.80) 2.99 (1.03) < 0.001
Vi/FVC 0.71 (0.22) 0.68 (0.24) 0.69 (0.21) 0.473
p values refer to controlled analysis of covariance.
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MDIs, or MDIs with new drug formulations, should be de-
signed with more resistance to airflow to naturally reduce the
speed of the inhalation flow. After the short inhalation tech-
nique training to increase inhalation to 5 sec, patient inhalation
time did increase by approximately 1 sec to almost 3 sec, and
as the inhalation volume was unchanged, inhalation flow was
therefore decreased. Of note, this training took less than 1min.
Perhaps if more time was spent on this aspect, then patients
would achieve the recommended 5-sec inhalation time,(9) and
inhalation flows would be slower than those measured.
In the schematic design, presented in Figure 2, when the
cap was fitted, then TsIn, theoretically, would be either zero
or negative. It would be zero because inhalation is not pos-
sible until the canister is depressed; however, because the Ti
measurement starts at the beginning of the inhalation flow,
then if the canister was depressed before the start of the
inhalation, TsIn would be negative. In this study, due to
limitations of the measurement method with the cap in place,
the airtight seal would be lost because of a small air leakage
through the mechanism that measures TsIn. Hence, TsIn
with the cap in place could not be measured. We have since
redesigned the measurement method such that TsIn can be
measured while maintaining an airtight system. This method
is currently being used in further studies that involve pa-
tients with more severe and uncontrolled asthma who have
poor MDI coordination.
The set of measurements using the MDI alone showed that
only two (2.8%) of the patients used a slow inhalation flow
with good coordination, consistent with previous observa-
tions.(7) With the coordination cap fitted (but without train-
ing), all patients would have had good coordination and 25
(35%) used a slow inhalation flow. The proportion using a
slow inhalation flow increased further to 50 (70%) patients
when the training (concerned with increasing the inhalation
period) was included. In clinical use with the cap fitted, this
would represent a large increase in the number of patients
with good coordination and slow inhalation flow. Previous
studies have shown the clinical benefit of a breath-actuated
inhaler(26) and that poor inhaler technique is partly due to
fast inhalation.(7,24) With the addition of the coordination
cap, training could focus primarily on the inhalation and
exhalation steps, without concerning the patient about
coordination.
The I-Breathe cap works by a different principle than
breath-actuated MDIs (such as Autohaler and Easi-
Breathe),(27) as it requires the patient to depress the canister.
On first use, 17 of the patients did not keep the canister de-
pressed throughout the duration of their inhalation, causing
the slits in the coordination cap to close and stop the patients
from continuing their inhalation through the inhaler.
FIG. 3. Inhalation parameter distributions for the inhala-
tion procedures, from the inhalation profile with the slower
PIF recorded for each patient. Circles represent outliers. (A)
PIF distributions. (B) Vi distributions. (C) Ti distributions.
Boxes represent the interquartile range with the median, and
the whiskers represent the full range of the data (excluding
the outliers, which are shown as circles).
Table 4. Patients Who Performed Slow (Correct)
Inhalation ( < 90 L/min), Fast Inhalation









< 90 (slow) 12 (16.9) 25 (35.2) 50 (70.4)
90–200 (fast) 41 (57.8) 42 (59.2) 21 (29.6)
> 200 (very fast) 18 (25.3) 4 (5.6) 0
CAP, coordination cap; TRAIN, instruction to inhale through the
MDI for a count of 5 (approximately 5 sec).
Of the duplicate inhalation maneuvers performed, the slower was
analyzed.
Table 5. Depth of Patients’ Inhalation









< 0.6 21 (29.6) 30 (42.3) 23 (32.4)
> 0.6 50 (70.4) 41 (57.8) 48 (67.6)
CAP, coordination cap; TRAIN, instruction to inhale through the
MDI for a count of 5 (approximately 5 sec).
Deep inhalation is defined as a Vi/FVC ratio of > 0.6.
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Although this could be regarded as a potential source of error,
patients did not repeat the mistake following instruction to
keep the canister depressed. Furthermore, no patient men-
tioned this possibility as a disadvantage in the open com-
ments. The fact that patients did not repeat the mistake or see
this as an issue could be due to the strong feedback mecha-
nism, whereby a halt in airflow following release of the can-
ister would encourage patients to keep the canister depressed
for the entire inhalation. Nevertheless, if this coordination cap
becomes available for general use, then the importance of
keeping the cap depressed will need to be highlighted in the
patient information leaflet and included in counseling.
We used a Vi/FVC ratio of > 0.6 to indicate a deep inha-
lation,(15) which was achieved by most patients. Although
greater lung deposition of drug occurs when exhaling to
residual volume compared with exhaling to functional re-
sidual capacity,(11) it has been shown that when using a slow
flow, inhalation at different stages of the vital capacity does
not affect lung deposition of the drug.(12,28) Receptors for
inhaled bronchodilators are distributed throughout the
lungs, but bronchodilators have their greatest effect in the
conducting airways due to the presence of smooth muscle
surrounding the airways.(29,30) Corticosteroid receptors are
also present throughout the airways, and inflammation has
been shown to exist in all regions of the lungs, especially in
asthma.(31) For these reasons, good lung penetration of the
aerosol dose is required. Patients should exhale before an
inhalation, and the inhalation should continue for as long as
possible,(9) but many patients make errors with these two
simple steps.(1,3)
Previous correlations of inhalation parameters to spirom-
etry have concentrated on peak inspiratory and expiratory
flow and have not been successful.(14,32–34) Our results
showed that FVC is a likely predictor of inhalation param-
eters when patients use an MDI. We did not include FEV1
because it correlated to FVC, and our preliminary statistical
analysis identified FVC rather than FEV1 as a predictor of
inhalation parameters.
Conclusion
A coordination cap together with a simple instruction to
lengthen the inhalation time when using an MDI ensures that
patients use the recommended slow inhalation flow with
good coordination. The coordination cap transforms a tra-
ditional MDI into an inhalation co-ordinating device, while
the increased resistance to airflow intuitively helps reduce
inhalation flow. Training the patient to extend the duration
of inhalation also led to reduced inhalation flow. With the
cap and simple instructions to inhale for 5 sec, 70% of pa-
tients would have achieved the correct MDI technique with
respect to coordination and inhalation flow.
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